RPL17 and neoplasm: To study the anti-tumor efficacy of PD-1 blockade in the context of PAK4 deletion, we treated syngeneic C57BL/6 mice (n=7 each group) bearing either B16 PAK4 KO or B16 WT tumors with anti-PD-1.